Magnus Expands Access to 5-Day SAINT® Depression Therapy as Leading Health Systems Scale Nationwide Adoption

• New SAINT programs launching at leading health systems, including Cleveland Clinic, UPMC and HCA Healthcare, expanding availability across 14 states
• Expanded payer approvals now provide access for more than 80 million covered lives including Medicare and commercial payers
• High-quality clinical evidence and ongoing research reinforce rapid remission and durable benefit of SAINT, driving adoption across treatment centers

BURLINGAME, Calif.--(BUSINESS WIRE)--Magnus Medical Inc., a pioneer in precision neuromodulation for brain health conditions, today announced growing commercial momentum as availability and access to its breakthrough SAINT® Depression Therapy increase, driven by expanding adoption among leading health systems, payer reimbursement, and patient demand.

Major depression continues to represent a significant and growing public health burden in the United States, with an estimated 47.8 million Americans affected¹ — underscoring a substantial unmet need for more effective, rapid-acting treatment options, as many patients experience inadequate response to existing standards of care. SAINT is the first and only FDA-cleared, accelerated 5-day, rapid-remission therapy for Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD), with pivotal clinical trials demonstrating that 79% of patients achieved remission in an average of just 2.6 days.

"For generations, treating depression has meant managing symptoms. SAINT is built on a different premise entirely: that by precisely mapping, targeting and treating the brain circuits underlying depression, we can achieve rapid, durable remission rather than incremental relief,” said Brandon Bentzley, M.D., Ph.D., co-founder and chief medical officer of Magnus Medical. “The adoption we’re seeing from leading health systems and payers reflects a growing recognition that this shift from symptom management to circuit-level intervention isn’t just possible — it’s here."

2025 marked an inflection point for Magnus that has accelerated into 2026, with additional leading health systems joining the Verified SAINT Provider network, commercial payers expanding reimbursement availability, and patient demand reaching new highs. Key measures of this progress include:

Availability of SAINT programs increasing across the U.S.

Magnus has expanded its health system partnerships to include Cleveland Clinic, University of Pittsburgh Medical Center (UPMC), HCA Healthcare, UTHealth Houston, Houston Methodist, Dartmouth-Hitchcock Medical Center, Sutter Health and OhioHealth, bringing SAINT to patients across a total of 14 states, with additional health system launches in new locations planned throughout 2026.

These additions build on an established base of early adopters including leading providers such as Stanford Health, Medical University of South Carolina (MUSC), University of Arkansas for Medical Sciences (UAMS), and University Medical Center New Orleans (LSU Health) as well as leading private psychiatry clinics nationwide.

Expanded payer reimbursement to reach more than 80 million covered lives

Magnus has made significant progress in expanding reimbursement for SAINT, with coverage now reaching more than 80 million lives across public and commercial payers. SAINT is reimbursable under Medicare Fee-for-Service (FFS) and a growing number of commercial plans. Self-pay options are also available at many treatment sites.

Advancing a high-quality evidence base that continues to drive adoption

Magnus continues to advance a rigorous and expanding scientific evidence base for SAINT, with accumulating data reinforcing its differentiated clinical profile, including among highly treatment-resistant populations. These findings are consistent across randomized controlled trials and multi-site real-world clinical practice, including heterogeneous patient populations with significant psychiatric, neurological, and medical comorbidity burden.

Across an aggregated dataset of over 200 patients, SAINT has demonstrated:

• Rapid onset of effect, with mean time to response of 2.3 days and remission of 2.6 days²
• High remission rates of 79% in randomized controlled trials³, with robust effect sizes and a low number needed to treat (NNT = 3.4)⁴
• Sustained clinical benefit lasting approximately 20 months⁵, with 100% of patients maintaining remission at one year with personalized retreatment protocols — 69.4% of which required only 1–2 days of retreatment⁶
• 89.1% of patients achieving clinically meaningful improvement within one week, including those with comorbid psychiatric, neurological, or sleep disorders⁷
• 44% reduction in anxiety symptoms among patients with comorbid anxiety⁸

Notably, SAINT has demonstrated complete acute remission of suicidality at one month (C-SSRS), underscoring its potential impact in high-risk populations² — a finding that carries particular significance given the unmet need in this patient group.

The commercial, clinical and reimbursement progress since early 2025 signals a clear and accelerating trajectory of broader SAINT adoption. With additional leading health systems preparing to launch SAINT programs in 2026, Magnus remains focused on its core mission of making rapid remission from depression accessible to every patient who needs it.

About Magnus

Magnus Medical Inc. is a privately held therapeutic neuromodulation company co-founded in 2020 to advance precision medicine in brain health. Its platform technology combines neuroimaging, proprietary targeting algorithms and individualized neurostimulation to address complex brain conditions. Magnus' first product, the SAINT neuromodulation system, is FDA-cleared for adults with major depressive disorder. For more information, visit https://www.magnusmedical.com.

About SAINT

The SAINT neuromodulation platform is the first FDA-cleared treatment for major depressive disorder that uses functional MRI data to guide personalized, noninvasive neuromodulation over an accelerated five-day schedule. SAINT has been designated a Breakthrough Device by the FDA and is the first mental health therapy to receive innovation support from CMS through the New Technology Add-on Payment and New Technology Ambulatory Payment Classification programs. In foundational studies, 79% of patients achieved remission in an average of 2.6 days. Clinical trials are ongoing for other neuropsychiatric conditions, including obsessive-compulsive disorder, bipolar depression and postpartum depression. These indications have not been cleared by the FDA. To learn more about SAINT, visit www.magnusmedical.com/depression-therapy/.

¹ Gallup. U.S. Depression Rate Remains Historically High. September 9, 2025. Available at: https://news.gallup.com/poll/694199/u.s.-depression-rate-remains-historically-high.aspx

² Cole et al. 2020. American Journal of Psychiatry. https://psychiatryonline.org/doi/10.1176/appi.ajp.2019.19070720

³ Cole et al. 2022. American Journal of Psychiatry. https://psychiatryonline.org/doi/10.1176/appi.ajp.2021.20101429

⁴ Kratter et al. 2026. World Psychiatry. https://onlinelibrary.wiley.com/doi/10.1002/wps.70032

⁵ Austelle et al. 2026. Presented at ADAA

⁶ Stimpson et al. 2026. Transcranial Magnetic Stimulation. https://doi.org/10.1016/j.transm.2025.100203

⁷ Geoly et al. 2026. Presented at ADAA

⁸ Geoly et al. 2026. Presented at ADAA